<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03664180</url>
  </required_header>
  <id_info>
    <org_study_id>2018024X</org_study_id>
    <secondary_id>BJUHFRIGHT201802</secondary_id>
    <nct_id>NCT03664180</nct_id>
  </id_info>
  <brief_title>Comparison of Anticoagulation Prolongation vs. no Anticoagulation in STEMI Patients After Primary PCI</brief_title>
  <acronym>RIGHT</acronym>
  <official_title>Randomized Comparison of Anticoagulation After Primary Percutaneous Coronary Intervention Using Enoxaparin, ACT Guided Unfractionated Heparin or Bivalirudin Prolongation vs. no Anticoagulation To Improve Clinical Outcome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Beijing Anzhen Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Chinese Academy of Medical Sciences, Fuwai Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>ACTION Study Group (Pitié-Salpêtrière Hospital), Paris, France</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Beijing Anzhen Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The RIGHT study is a large randomized study dedicated to post-PPCI anticoagulation in STEMI&#xD;
      patients. The investigators propose to evaluate the clinical efficacy and safety of&#xD;
      anticoagulation prolonged for at least 48 hours after the procedure vs. no prolongation of&#xD;
      anticoagulation after procedure in patients with STEMI treated with bivalirudin during PPCI&#xD;
      (primary hypothesis). When allocated to anticoagulation prolongation by randomization, the&#xD;
      subject will be assigned to UFH, enoxaparin or bivalirudin (same regimen allocated by centre)&#xD;
      for at least 48 hours after PPCI. The results from this study are expected to provide&#xD;
      guidance on the risk/benefit of post-procedural anticoagulation in patients with STEMI.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A minor change of time of randomization after prolongation of bivalirudin infusion at PCI&#xD;
      dose up to 4 hours on protocol at September 19,2018. Reasons: a minor change concerning the&#xD;
      timing of randomization considering the current local practice in some centers that use the 4&#xD;
      hour infusion of bivalirudin just after PCI. It remains in agreement with the current&#xD;
      international guidelines and with the drug label in China. There is no change in drugs used&#xD;
      and doses of these drugs once the randomization occurs.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 11, 2019</start_date>
  <completion_date type="Anticipated">December 2022</completion_date>
  <primary_completion_date type="Anticipated">December 2021</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Primary efficacy endpoint - number of event of a composite of all-cause death, non-fatal myocardial infarction, non-fatal stroke, stent thrombosis (definite) or urgent revascularization (any vessel)</measure>
    <time_frame>30 days</time_frame>
    <description>The number of event of a composite of all-cause death, non-fatal myocardial infarction, non-fatal stroke, stent thrombosis (definite) or urgent revascularization (any vessel) within 30 days after randomization</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Primary safety endpoint - The number of event of major bleeding</measure>
    <time_frame>30 days</time_frame>
    <description>The number of event of major bleeding (BARC 3 to 5) within 30 days after randomization</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Secondary ischemic endpoints - The number of event of a composite of all-cause death, non-fatal myocardial infarction, or non-fatal stroke</measure>
    <time_frame>30 days</time_frame>
    <description>The number of event of a composite of all-cause death, non-fatal myocardial infarction, or non-fatal stroke within 30 days after randomization</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Secondary ischemic endpoints - The number of event of a composite of all-cause death or non-fatal myocardial infarction</measure>
    <time_frame>30 days</time_frame>
    <description>The number of event of a composite of all-cause death or non-fatal myocardial infarction within 30 days after randomization</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Secondary ischemic endpoints - The number of cardiovascular death events</measure>
    <time_frame>30 days</time_frame>
    <description>The number of cardiovascular death event within 30 days after randomization</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Secondary ischemic endpoints - The number of stent thrombosis (ARC definite) events</measure>
    <time_frame>30 days</time_frame>
    <description>The number of stent thrombosis (ARC definite) event within 30 days after randomization</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Secondary safety endpoints - The number of bleeding events (TIMI, STEEPLE and GUSTO definition)</measure>
    <time_frame>30 days</time_frame>
    <description>The number of bleeding events (TIMI, STEEPLE and GUSTO definition) within 30 days after randomization&#xD;
To demonstrate that post-procedure anticoagulation with UFH, enoxaparin or bivalirudin as compared to their placebo is associated to lower rate of the composite endpoint of major bleeding according to TIMI, STEEPLE and GUSTO definitions within the first 30 days after randomization.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Secondary safety endpoints - The number of thrombocytopenia events</measure>
    <time_frame>30 days</time_frame>
    <description>The number of thrombocytopenia events within 30 days after randomization&#xD;
To demonstrate superiority of a strategy of post-procedure anticoagulation with UFH, enoxaparin or bivalirudin as compared to their placebo by the time from randomization to the first occurrence of any event of the Thrombocytopenia endpoint over 30 days of follow-up.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">2856</enrollment>
  <condition>STEMI - ST Elevation Myocardial Infarction</condition>
  <arm_group>
    <arm_group_label>anticoagulation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>No anticoagulation</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bivalirudin</intervention_name>
    <description>IV infusion of 0.2 mg/kg/h (low-rate infusion) for at least 48h after the procedure or until discharge from CCU if it occurs later</description>
    <arm_group_label>anticoagulation</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Enoxaparin</intervention_name>
    <description>40mg/d s.c.for at least 48h after the procedure or until discharge from CCU if it occurs later</description>
    <arm_group_label>anticoagulation</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Unfractionated heparin</intervention_name>
    <description>IV infusion of 10 U/kg/h (maximum 1000 U) initially, adjusted to maintain ACT between 150 and 220 seconds for at least 48h after the procedure or until discharge from CCU if it occurs later</description>
    <arm_group_label>anticoagulation</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bivalirudin placebo</intervention_name>
    <description>Matching placebo IV infusion for at least 48h after the procedure or until discharge from CCU if it occurs later</description>
    <arm_group_label>No anticoagulation</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Enoxaparin placebo syringe</intervention_name>
    <description>Placebo syringe will be only prepared by a designated unblended medical professional on site. Placebo syringe will be presented in identical containers as a clear, colorless, sterile liquid of saline.Subcutaneous injection once a day for at least 48 hours after the procedure or until discharge from CCU if it occurs later.</description>
    <arm_group_label>No anticoagulation</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Unfractionated heparin placebo</intervention_name>
    <description>Matching placebo IV infusion for at least 48h after the procedure or until discharge from CCU if it occurs later.</description>
    <arm_group_label>No anticoagulation</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age ≥18 years old&#xD;
&#xD;
          -  STEMI with PPCI of culprit lesion&#xD;
&#xD;
          -  Bivalirudin therapy during PPCI&#xD;
&#xD;
          -  Signed informed consent form&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients with a formal indication for anticoagulation after PPCI (e.g. atrial&#xD;
             fibrillation, left-ventricular thrombus, intra-aortic balloon pump, pulmonary&#xD;
             embolism, mechanical heart valve)&#xD;
&#xD;
          -  Patients with any indication for chronic anticoagulation&#xD;
&#xD;
          -  Patient with previous lytic treatment&#xD;
&#xD;
          -  Patient with previous coronary artery bypass graft surgery&#xD;
&#xD;
          -  Cardiogenic shock, malignant ventricular arrhythmia, or mechanical complications&#xD;
&#xD;
          -  Any anticoagulation other than bivalirudin started after the procedure before&#xD;
             randomization&#xD;
&#xD;
          -  Estimated body weight of &gt;120 kg or &lt;45kg&#xD;
&#xD;
          -  BP ≥180/110mmHg at randomization&#xD;
&#xD;
          -  Any bleeding diathesis or severe hematologic disease or history of intracerebral mass,&#xD;
             aneurysm, arteriovenous malformation, recent (&lt;6months) ischemic stroke or TIA, recent&#xD;
             (&lt;6months) intracranial hemorrhage or, gastrointestinal or genitourinary bleeding&#xD;
             within the past 2 weeks&#xD;
&#xD;
          -  History of heparin-induced thrombocytopenia&#xD;
&#xD;
          -  Suspected acute aortic dissection (AAD)&#xD;
&#xD;
          -  Major surgery within 1 month&#xD;
&#xD;
          -  A planned elective surgical procedure that would necessitate an interruption in&#xD;
             treatment with P2Y12 inhibitors in the next 6 months after enrollment&#xD;
&#xD;
          -  Known PLT≤100×109 or HGB≤10g/L&#xD;
&#xD;
          -  Known transaminase &gt;3-fold ULN, or CCr&lt;30ml/min&#xD;
&#xD;
          -  Known allergy to any study drug&#xD;
&#xD;
          -  Pregnancy or lactation&#xD;
&#xD;
          -  Noncardiac coexisting conditions that could limit life expectancy to less than 1 year&#xD;
&#xD;
          -  Current participation in an investigational drug or device trial&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Shao-Ping Nie, MD, PhD</last_name>
    <phone>86-10-84005256</phone>
    <email>spnie@ccmu.edu.cn</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Yan Yan, MD</last_name>
    <phone>+86-10-84005255</phone>
    <email>eva3321@sina.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Beijing Anzhen Hospital, Capital Medical University</name>
      <address>
        <city>Beijing</city>
        <zip>100029</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shao-Ping Nie, MD, PhD</last_name>
      <phone>86-10-84005256</phone>
      <email>spnie@ccmu.edu.cn</email>
    </contact>
    <investigator>
      <last_name>Shao-Ping Nie, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <reference>
    <citation>Yan Y, Wang X, Guo J, Li Y, Ai H, Gong W, Que B, Zhen L, Lu J, Ma C, Montalescot G, Nie S. Rationale and design of the RIGHT trial: A multicenter, randomized, double-blind, placebo-controlled trial of anticoagulation prolongation versus no anticoagulation after primary percutaneous coronary intervention for ST-segment elevation myocardial infarction. Am Heart J. 2020 Sep;227:19-30. doi: 10.1016/j.ahj.2020.06.005. Epub 2020 Jun 20.</citation>
    <PMID>32663660</PMID>
  </reference>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>August 27, 2018</study_first_submitted>
  <study_first_submitted_qc>September 7, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">September 10, 2018</study_first_posted>
  <last_update_submitted>January 8, 2021</last_update_submitted>
  <last_update_submitted_qc>January 8, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 11, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Beijing Anzhen Hospital</investigator_affiliation>
    <investigator_full_name>Shao-Ping Nie</investigator_full_name>
    <investigator_title>Professor of Medicine, Director, Emergency &amp; Critical Care Center</investigator_title>
  </responsible_party>
  <keyword>anticoagulantion</keyword>
  <keyword>post-procedure</keyword>
  <keyword>STEMI</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Myocardial Infarction</mesh_term>
    <mesh_term>ST Elevation Myocardial Infarction</mesh_term>
    <mesh_term>Infarction</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heparin</mesh_term>
    <mesh_term>Calcium heparin</mesh_term>
    <mesh_term>Enoxaparin</mesh_term>
    <mesh_term>Hirudins</mesh_term>
    <mesh_term>Enoxaparin sodium</mesh_term>
    <mesh_term>Bivalirudin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

